Invest in

Drug-Patent Cliffs

26.1%
1.1%
0.0%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
26.1%
1.1%
0.0%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 23.0%
22.1% Dr. Reddy's Laboratories Ltd RDY 7.0%
19.7% Taro Pharmaceutical Industries Ltd. TARO 29.3%
18.8% Mylan N.V. MYL 32.7%
9.3% Abbott Laboratories ABT 13.4%
7.8% The Medicines Company MDCO 16.6%
6.1% Mallinckrodt plc MNK 28.8%
5.6% Akorn Inc. AKRX 50.1%
5.3% Impax Laboratories Inc. IPXL 69.6%
2.7% Lannett Co Inc LCI 39.2%
1.6% Cambrex Corporation CBM 3.2%
0.9% Endo International PLC ENDP 74.5%

Quotes delayed 15 mins. Currently Dec 9, 2016 6:34:39 AM. Fields are marked with -- when data is unavailable.